Summary:
A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Qualified Participants Must:
• Have Chronic Atopic Dermatitis that has been present for at least 3 years before the screening visit
•
Have ≥10% body surface area (BSA) of Atopic Dermatitis involvement at the screening and baseline visits
•
Have documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks)
•
More inclusion/exclusion criteria apply
Qualified Participants May Receive:
Compensation for time and travel as well as receive the study medication and all study-related exams, labs, and office visits at no cost to you.